Pharmacology of Inflammation.
Dr Steve Taylor's research interests involve the development of new anti-inflammatory drugs. New agents developed in collaboration with IMB include orally active C5a antagonists, phospholipase A2 inhibitors, and the development of other anti-complement drugs.
Inhibiting inflammatory processes with novel drug classes such as these offers therapeutic benefits for a range of disorders currently poorly treated with anti-inflammatory drugs, such as rheumatoid arthritis, multiple sclerosis, Alzheimer's disease and reperfusion injury.
The results of this work has resulted in the filing of several patents, and the formation of a UQ startup company, Promics Pty Ltd, which has resulted in human clinical trials of a lead C5a receptor antagonist.
The development of new classes of anti-inflammatory drugs to treat currently intractable human immune and inflammatory diseases is the basis of the research endeavour.